Market Place
Sourcing Support
Tiefenbacher Group at CPHI Frankfurt 2025
24 Oct 2025 //
PRESS RELEASE
Celebrating the Spirit of Diwali at Tiefenbacher Laboratories
20 Oct 2025 //
PRESS RELEASE
Tiefenbacher Group and Neuraxpharm announce the launch of Riulvy
10 Oct 2025 //
PRESS RELEASE
Tiefenbacher Group Career Stories No 3
29 Aug 2025 //
PRESS RELEASE
Tiefenbacher Group celebrates World Humanitarian Day
20 Aug 2025 //
PRESS RELEASE
Tiefenbacher Group Career Stories No 2
15 Aug 2025 //
PRESS RELEASE
Tiefenbacher Group Career Stories No 1
05 Aug 2025 //
PRESS RELEASE
Tiefenbacher New Market Launch: Buprenorphine Patches in SA
01 Aug 2025 //
PRESS RELEASE
Tiefenbacher Group Self-Care Day
25 Jul 2025 //
PRESS RELEASE
Pioneering Healthcare at Tiefenbacher Group
23 Jul 2025 //
PRESS RELEASE
Tiefenbacher Group about affordable medicines
10 Jul 2025 //
PRESS RELEASE
Tiefenbacher Group International Social Day
01 Jul 2025 //
PRESS RELEASE
Tiefenbacher Laboratories Supporting Women’s Health
28 May 2025 //
PRESS RELEASE
Tiefenbacher Group celebrates World Health Day
07 Apr 2025 //
PRESS RELEASE
Tiefenbacher Group celebrating new buildings in Hyderabad
25 Mar 2025 //
PRESS RELEASE
Tiefenbacher, OnDosis & Star celebrate iF Design Award for OYSTA
10 Mar 2025 //
PRESS RELEASE
Lindus Health, Tiefenbacher Group Launch ME/CFS Clinical Trial
06 Mar 2025 //
PR NEWSWIRE
Tiefenbacher Pharmaceuticals Launch: Varenicline in UK
05 Feb 2025 //
PRESS RELEASE
Tiefenbacher Pharmaceuticals New Market Launch: Amifampridine
30 Jan 2025 //
PRESS RELEASE
Tiefenbacher Group and Pharmacists Without Borders
21 Nov 2024 //
PRESS RELEASE
Pioneering Healthcare at Tiefenbacher Group
02 Oct 2024 //
PRESS RELEASE
Tiefenbacher Pharma New Market Launch Ezetimibe/Atorvastatin
18 Sep 2024 //
PRESS RELEASE
Tiefenbacher Group Earns EcoVadis Silver Medal!
09 Sep 2024 //
PRESS RELEASE
Tiefenbacher PharmaFirst to Market Launch Varenicline in Europe
22 Aug 2024 //
PRESS RELEASE
Tiefenbacher Group partnering with Pharmacists Without Borders
01 Aug 2024 //
PRESS RELEASE
Tiefenbacher Group Renovation Of Headquarters In Hamburg
02 May 2024 //
PRESS RELEASE
Tiefenbacher Pharmaceuticals successfully prepares the launch of the anticoagulant Rivaroxaban.
09 Apr 2024 //
PRESS RELEASE
Tiefenbacher Group welcome our new COO for AET Laboratories, Sandip Tarate
08 Apr 2024 //
PRESS RELEASE
Tiefenbacher Group awarded the EcoVadis Silver Medal!
19 Mar 2024 //
PRESS RELEASE
Tiefenbacher Group on awareness for rare disease day
29 Feb 2024 //
PRESS RELEASE
Tiefenbacher Group Renovation of our Headquarters
14 Feb 2024 //
PRESS RELEASE
Tiefenbacher Pharmaceuticals Launch Of Generic Teriflunomide
27 Sep 2023 //
PRESS RELEASE
New Websites Online
06 Jun 2023 //
PRESS RELEASE
Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority
10 May 2023 //
PRESS RELEASE
Tiefenbacher Pharma Successfully Launches The Antihistamine Bilastine
14 Mar 2023 //
PRESS RELEASE
Tiefenbacher Manufacturing Sites Have Been Successfully Registered By The UAE
25 Feb 2023 //
PRESS RELEASE
Tiefenbacher Successfully Launches Generic Version Of The Psoriasis Apremilast
01 Dec 2022 //
PRESS RELEASE
Thanks For Visiting Us At Cphi 2022 In Frankfurt!
10 Nov 2022 //
PRESS RELEASE
Tiefenbacher Group Opens New Manufacturing Site In Cyprus
28 Oct 2022 //
PRESS RELEASE
Tiefenbacher Group And Ondosis Are Thrilled To Announce The Launch Of Oysta®
25 Oct 2022 //
PRESS RELEASE
Tiefenbacher Pharma Successfully Launches Generic Version Apixaban In Canada
20 Oct 2022 //
PRESS RELEASE
Meet Tiefenbacher At Cphi In Frankfurt From 1-3 Nov & Discover Our Latest Ideas
04 Oct 2022 //
PRESS RELEASE
Meet Tiefenbacher Group At Bepharma In Mexico City From October 10-12!
15 Sep 2022 //
PRESS RELEASE
Tiefenbacher Successfully Launches Generic Version Diabetis Med Vildagliptin
08 Sep 2022 //
PRESS RELEASE
Environmentally Friendly And Health-Promoting: Tiefenbacher Group Offers Bike
18 Aug 2022 //
PRESS RELEASE
Tiefenbacher Expands The Launch Of The Anticoagulant Medicine Rivaroxaban
15 Jul 2022 //
PRESS RELEASE
Tiefenbacher Launches 1st Generic Version Of MS Medicine Teriflunomide In Canada
02 Jun 2022 //
PRESS RELEASE
Tiefenbacher Group Becomes Member Of (Psci)
24 May 2022 //
PRESS RELEASE
Tiefenbacher Group Opens New Site For Highly Potent Drugs In India
05 May 2022 //
PRESS RELEASE
Four Drugs Recommended For Approval By Chmp At April Meeting
25 Apr 2022 //
MEDWATCH
World Health Day @ Tiefenbacher Group
07 Apr 2022 //
PRESS RELEASE
Tiefenbacher Group At Dcat 2022 – Thanks For Meeting Us In New York City!
29 Mar 2022 //
PRESS RELEASE
New Launch: Tiefenbacher Pharma Successfully Launches First Generic Version
22 Mar 2022 //
PRESS RELEASE
Tiefenbacher Group Stands With Ukraine
09 Mar 2022 //
PRESS RELEASE
Tiefenbacher Group Stands With Ukraine
08 Mar 2022 //
PRESS RELEASE
Meet Tiefenbacher Group During Dcat Week In New York City From 21-24Th March!
09 Feb 2022 //
PRESS RELEASE
Tiefenbacher Group Wishes A Happy And Healthy Year 2022 From All Over The World!
04 Jan 2022 //
PRESS RELEASE
Tiefenbacher Group Wishes A Happy And Healthy New Year 2022 From All Over
04 Jan 2022 //
PRESS RELEASE
Driving Efficiency Is Key Tiefenbacher Group Enlarges Manufacturing Facilities
15 Dec 2021 //
PRESS RELEASE
Driving efficiency is our key – TIEFENBACHER GROUP its MFG facilities De15, 2021
15 Dec 2021 //
PRESS RELEASE
